BCMA Assay Portfolio Service
With unrivaled expertise and experiences in immune-oncology discovery and development, Creative Biolabs is confident in providing an integrated solution for BCMA assay services to best suit your program requirements.
Tumor Target BCMA
B-cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a 20.2 kDa type III transmembrane glycoprotein, belonging to the TNFR superfamily. BCMA is preferentially expressed in mature B lymphocytes, while with low expression in hematopoietic stem cells or nonhematopoietic tissue.
BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF), which are mainly secreted by the bone marrow (BM) stromal cells, osteoclasts and macrophages. When the ligands bind to BCMA, multiple growth and survival signaling cascades are activated in multiple myeloma (MM) cells, including NF-κβ, RAS/MAPK and PI3K-PKB/Akt signaling pathways.
Fig.1 BCMA signaling pathway. (Yu, 2020)
BCMA-Targeted Immunotherapy for MM
Due to the highly selective expression in malignant plasma cells (PCs), BCMA has been considered a promising target for MM therapies. Currently, multiple BCMA-targeted therapeutics have achieved remarkable clinical responses in MM. In brief, three main therapies are targeting BCMA in MM market, including BiTE (bispecific T-cell engager) immuno-oncology therapies, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR)-modified T-cell therapies. Representative cases include the BiTE molecule AMG 420, ADC GSK2857916 and CAR T-cell therapies NIH CAR-BCMA, LCAR-B38M.
Fig.2 BCMA-targeted immunotherapies.(Yu, 2020)
Our BCMA Assay Portfolio Services
To better study the potential of BCMA target, Creative Biolabs offers high-quality BCMA assay portfolio services to help our clients meet their program requirements. We are committed to providing more comprehensive and accurate analytical results, covering the initial target validation in vitro to the later preclinical analysis to meet the requirements of scientific research.
For more details of our BCMA assay portfolio services, please don’t hesitate to contact us for more information.
Reference
-
Yu, B.; et al. BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology & Oncology. 2020,13(1): 1-24.
For Research Use Only | Not For Clinical Use
Download our brochure